CG Oncology to present latest data on Cretostimogene Grenadenorepvec at SUO 2024 annual meeting
CG Oncology, Inc, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that four Trials… read more.
